Piperine potentiates the antidepressant-like effect of trans-resveratrol: Involvement of monoaminergic system

Metabolic Brain Disease

Volumn 28, Issue 4, 2013, Pages 585-595

  Huang, Wu ^a,b   Chen, Zhuoyou ^a,b   Wang, Qiandong ^a   Lin, Mengmeng ^a   Wu, Shujuan ^a   Yan, Qizhi ^a   Wu, Fan ^a   Yu, Xuefeng ^a   Xie, Xupei ^a   Li, Gaowen ^c   Xu, Ying ^a,d   Pan, Jianchun ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED CHANGZHOU NO 2 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c Ningbo College of Health Sciences   (China)

^d WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Depression; MAO; Monoamine; Piperine; Synergistic effect; Trans resveratrol

Indexed keywords

PIPERINE; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; EXPERIMENTAL TEST; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; INDUCED HYPOTHERMIA; LOCOMOTION; LOW DRUG DOSE; MALE; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; PTOSIS; TAIL SUSPENSION TEST;

MUS; POLYGONUM CUSPIDATUM;

ALKALOIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZODIOXOLES; BRAIN; DEPRESSION; DRUG SYNERGISM; HINDLIMB SUSPENSION; MICE; MONOAMINE OXIDASE; MOTOR ACTIVITY; PIPERIDINES; POLYUNSATURATED ALKAMIDES; SEROTONIN; STILBENES; SWIMMING;

EID: 84887238400     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-013-9426-y     Document Type: Article

References (45)

1. Arora V, Kuhad A, Tiwari V, Chopra K (2011) Curcumin ameliorates reserpine-induced pain-depression dyad: behavioral, biochemical, neurochemical and molecular evidences. Pychoneuroendocrinology 36:1570-1581
2. Bai XP, Li HL, Yang WY, Xiao JZ, Wang B, Lou DJ, Du RQ (2011) Sequence of fat partitioning and its relationship with whole body insulin resistance. Chin Med J 36:3605-3611
3. Bhutani MK, Bishnoi M, Kulkarni SK (2009) Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav 92:39-43
4. Bourin M, Mocaër E, Porsolt R (2004) Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatr Neurosci 29:126-133
5. Bourin M, Poncelet M, Chermat R, Simon P (1983) The value of the reserpine test in psychopharmacology. Arzneimittelforschung 33:1173-1176
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
7. Butterweck V, Bockers T, Korte B, Bittkowski W, Winterhoff H (2002) Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res 930:21-29
8. Chakrabarti SK, Loua KM, Bai C, Durham H, Panisset JC (1998) Modulation of monoamine oxidase activity in different brain regions and platelets following exposure of rats to methylmercury. Neurotoxicol Teratol 20:161-168
9. Chen X, Zhang N, Zou HY (2007) Protective effect of baicalin on mouse with Parkinson's disease induced by MPTP. Zhongguo Zhong Xi Yi Jie He Za Zhi 27:1010-1012
10. Clausius N, Born C, Grunze H (2009) The relevance of dopamine agonists in the treatment of depression. Neuropsychiatric 23:15-25
11. D'Aquila PA, Collu M, Gessa GL, Serra G (2000) The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 34:S29-S37
12. Dhir A, Naidu PS, Kulkarni SK (2005) Effect of naproxen, a non-selective cyclo-oxygenase inhibitor, on pentylenetetrazol-induced kindling in mice. Clin Exp Pharmacol Physiol 32:574-584
13. Elliott PJ, Jirousek M (2008) Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 9:371-378
14. El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM (2001) Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol 134:68-77
15. Heydendael W, Jacobson L (2008) Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response. Brain Res 1238:93-107
16. Horn TL, Cwik MJ, Morrissey RL, Kapetanovic I, Crowell JA, Booth TD, McCormick DL (2007) Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice. Food Chem Toxicol 45:55-63
17. Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H, Ahmad N (2011) Enhancing the bioavailability of resveratrol by combining it with piperine. Nutr Food Res 55:169-176
18. Kato M, Katayama T, Iwata H, Yamamura M, Matsuoka Y, Narita H (1998) In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin. J Pharmacol Exp Ther 284:983-990
19. Khajuria A, Thusu N, Zutshi U (2002) Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 9:224-231
20. Kohane MJ, Watt WB (1999) Flight-muscle adenylate pool responses to flight demands and thermal constraints in individual Colias eurytheme (Lepidoptera, pieridae). J Exp Biol 202:3145-3154
21. Kulkarni SK, Dhir A (2008) On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol 589:163-172
22. Kwon S, Lee B, Kim M, Lee H, Park HJ, Hahm DH (2010) Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test. Progr Neuro Psychopharmacol Biol Psychiatr 34:265-270
23. Lam RW, Wan DD, Cohen NL, Kennedy SH (2002) Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatr 63:685-693
24. Li S, Wang C, Wang M, Li W, Matsumoto K, Tang Y (2007) Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms. Life Sci 80:1373-1381
25. Montgomery SA (1997) Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 7:S3-S9
26. Ndiaye M, Kumar R, Ahmad N (2011) Resveratrol in cancer management: where are we and where we go from here? Ann New York Acad Sci 1215:144-149
27. Nemeroff CB (2007) Stress, menopause and vulnerability for psychiatric illness. Expert Rev Neurother 11:S11-S13
28. Nitta J, Akazaki T, Takayanagi H, Arai K (1992) Transport properties in an InAs-inserted-channel In0.52Al0.48As/In0.53Ga0.47As heterostructure coupled superconducting junction. Phys Rev B Condens Matter 46:14286-14289
29. Ogle WO, Speisman RB, Ormerod BK (2013) Potential of treating age-related depression and cognitive decline with nutraceutical approaches: a mini-review. Gerontology 59:23-31
30. Pathak L, Agrawal Y, Dhir A (2013) Natural polyphenols in the management of major depression. Expert Opin Investig Drugs 22:863-880
31. Pineyro G, Blier P (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51:533-591
32. Porsolt RD, Bertin A, Jalfre M (1978) "Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 51:291-294
33. Ranney A, Petro MS (2009) Resveratrol protects spatial learning in middle-aged C57BL/6 mice from effects of ethanol. Behav Pharmacol 20:330-336
34. Redrobe JP, Dumont Y, Fournier A, Baker GB, Quirion R (2005) Role of serotonin (5-HT) in the antidepressant-like properties of neuropeptide Y (NPY) in the mouse forced swim test. Peptides 26:1394-1400
35. Rinwa P, Kumar A, Garg S (2013) Suppression of neuroinflammatory and apoptotic signaling cascade by curcumin alone and in combination with piperine in rat model of olfactory bulbectomy induced depression. PLoS One 8:e61052
36. Rubio G, San L, López-Muñoz F, Alamo C (2004) Reboxetine adjunct for partial or nonresponders to antidepressant treatment. J Affect Disord 81:67-72
37. Tak JK, Lee JH, Park JW (2012) Resveratrol and piperine enhance radiosensitivity of tumor cells. Biochem Mol Biol Rep 45:242-246
38. Tredici G, Miloso M, Nicolini G, Galbiati S, Cavaletti G, Bertelli A (1999) Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant? Drugs Exp Clin Res 25:99-103
39. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C (2010) Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC cancer 10:238
40. Xu Y, Cai W, Hu JB, Shi QC, Li L (2005a) Levels of common knowledge on common psychiatric disorders and therapeutic means taken in general population: effects of education level and living area. Zhonghua Yu Fang Yi Xue Za Zhi 39:237-240
41. Xu Y, Ku BS, Yao HY, Lin YH, Ma X, Zhang YH, Li XJ (2005b) Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav 82:200-206
42. Xu Y, Liu H, Li F, Sun N, Ren Y, Liu Z, Cao X, Wang Y, Liu P, Zhang K (2010a) A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform. J Affect Disord 127:332-336
43. Xu Y, Wang Z, Zhang X, Li S, Barish PA, Vernon MM, Du X, Li G, Pan J, Ogle WO (2010b) Antidepressant-like effect of trans-resveratrol: involvement of serotonin and noradrenaline system. Eur Neuropsychopharmacol 20:405-413
44. Yi LT, Xu Q, Li YC, Yang L, Kong LD (2009) Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice. Progr Neuro Psychopharmacol Biol Psychiatr 33:616-624
45. Yu ZF, Kong LD, Chen Y (2002) Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 83:161-165